Biopharmx Corp (NYSEAMERICAN:BPMX) shares were up 6.8% during mid-day trading on Tuesday . The company traded as high as $0.48 and last traded at $0.47, approximately 721,900 shares traded hands during mid-day trading. An increase of 15% from the average daily volume of 628,032 shares. The stock had previously closed at $0.44.
Separately, Maxim Group reaffirmed a “buy” rating and issued a $1.00 target price on shares of Biopharmx in a report on Friday, December 13th.
The company’s 50-day moving average price is $0.35.
Biopharmx (NYSEAMERICAN:BPMX) last released its quarterly earnings results on Tuesday, December 10th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.08.
An institutional investor recently bought a new position in Biopharmx stock. Barclays PLC purchased a new stake in Biopharmx Corp (NYSEAMERICAN:BPMX) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 175,000 shares of the biotechnology company’s stock, valued at approximately $58,000. Barclays PLC owned about 1.23% of Biopharmx at the end of the most recent quarter.
Biopharmx Company Profile (NYSEAMERICAN:BPMX)
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Featured Article: Coverage Ratio
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.